Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare investments.
Shionogi, a major Japanese pharmaceutical company, is explicitly named as a backer of Apnimed's $160 million US IPO. A successful IPO would likely increase the perceived value of Shionogi's investment, potentially boosting its stock price. Conversely, any delays or weak demand could weigh on sentiment. The offering underscores Shionogi's strategic commitment to external innovation in sleep medicine.
The article does not specify Shionogi's stake, but its backing suggests a notable equity position that could lead to gains upon listing.
Only indirectly through potential marked-to-market gains on the investment, though a successful exit could unlock capital for Shionogi's pipeline.
Shionogi has a growing presence in the US with partnerships and stakes in biotech firms, aiming to diversify beyond its domestic market.
Biotech firm Apnimed, backed by Japanese pharmaceutical company Shionogi, plans to raise $160 million through an initial public offering in the United States. The IPO could provide capital for Apnimed's clinical-stage pipeline and may value the company at a significant premium, benefiting Shionogi's investment arm. The listing adds to a busy US IPO calendar despite volatile market conditions.
A biotech company developing treatments for sleep disorders, backed by Shionogi.
It marks a sizable offering in the biotech sector, reflecting investor demand and cross-border backing.
Shionogi's stake could see a valuation boost upon a successful IPO, providing a return on its investment.